Furthermore, we explored the correlation between ARID1A mutations and immune checkpoint blockade therapy response using three cancer immunotherapy (anti-PD-1/PD-L1/CTLA-4) response-associated cohorts (Allen cohort [3], Hugo cohort [31], and Samstein cohort [32]). This evidence concerns the gene PDCD1 and cancer.